135 related articles for article (PubMed ID: 15188221)
1. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model.
Langer T; Eder M; Hoffmann RD; Chiba P; Ecker GF
Arch Pharm (Weinheim); 2004 Jun; 337(6):317-27. PubMed ID: 15188221
[TBL] [Abstract][Full Text] [Related]
2. Intramolecular distribution of hydrophobicity influences pharmacological activity of propafenone-type MDR modulators.
Pleban K; Hoffer C; Kopp S; Peer M; Chiba P; Ecker GF
Arch Pharm (Weinheim); 2004 Jun; 337(6):328-34. PubMed ID: 15188222
[TBL] [Abstract][Full Text] [Related]
3. Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance.
Kaiser D; Smiesko M; Kopp S; Chiba P; Ecker GF
Med Chem; 2005 Sep; 1(5):431-44. PubMed ID: 16787327
[TBL] [Abstract][Full Text] [Related]
4. QSAR and 3D-QSAR of phenothiazine type multidrug resistance modulators in P388/ADR cells.
Tsakovska IM
Bioorg Med Chem; 2003 Jul; 11(13):2889-99. PubMed ID: 12788359
[TBL] [Abstract][Full Text] [Related]
5. A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance.
Tmej C; Chiba P; Huber M; Richter E; Hitzler M; Schaper KJ; Ecker G
Arch Pharm (Weinheim); 1998; 331(7-8):233-40. PubMed ID: 9747179
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.
Jabeen I; Pleban K; Rinner U; Chiba P; Ecker GF
J Med Chem; 2012 Apr; 55(7):3261-73. PubMed ID: 22452412
[TBL] [Abstract][Full Text] [Related]
7. Self-organizing maps for identification of new inhibitors of P-glycoprotein.
Kaiser D; Terfloth L; Kopp S; Schulz J; de Laet R; Chiba P; Ecker GF; Gasteiger J
J Med Chem; 2007 Apr; 50(7):1698-702. PubMed ID: 17352460
[TBL] [Abstract][Full Text] [Related]
8. MCASE study of the multidrug resistance reversal activity of propafenone analogs.
Klopman G; Zhu H; Ecker G; Chiba P
J Comput Aided Mol Des; 2003; 17(5-6):291-7. PubMed ID: 14635722
[TBL] [Abstract][Full Text] [Related]
9. Propafenone analogue with additional H-bond acceptor group shows increased inhibitory activity on P-glycoprotein.
Cseke A; Schwarz T; Jain S; Decker S; Vogl K; Urban E; Ecker GF
Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900269. PubMed ID: 31917466
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivity.
Fleischer R; Wiese M
J Med Chem; 2003 Nov; 46(23):4988-5004. PubMed ID: 14584949
[TBL] [Abstract][Full Text] [Related]
12. Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.
Murumkar PR; Zambre VP; Yadav MR
J Comput Aided Mol Des; 2010 Feb; 24(2):143-56. PubMed ID: 20179991
[TBL] [Abstract][Full Text] [Related]
13. Modeling study of phenylsulfonylfuroxan derivatives as P-gp inhibitors: a combined approach of CoMFA, CoMSIA and HQSAR.
Gadhe CG; Balupuri A; Balasubramanian PK; Cho SJ
Anticancer Agents Med Chem; 2014; 14(7):1019-30. PubMed ID: 24066798
[TBL] [Abstract][Full Text] [Related]
14. In silico quantitative structure-activity relationship studies on P-gp modulators of tetrahydroisoquinoline-ethyl-phenylamine series.
Gadhe CG; Madhavan T; Kothandan G; Cho SJ
BMC Struct Biol; 2011 Jan; 11():5. PubMed ID: 21269449
[TBL] [Abstract][Full Text] [Related]
15. 2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein.
Jabeen I; Wetwitayaklung P; Chiba P; Pastor M; Ecker GF
J Comput Aided Mol Des; 2013 Feb; 27(2):161-71. PubMed ID: 23400406
[TBL] [Abstract][Full Text] [Related]
16. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.
Mustyala KK; Chitturi AR; Naikal James PS; Vuruputuri U
J Recept Signal Transduct Res; 2012 Apr; 32(2):102-13. PubMed ID: 22384789
[TBL] [Abstract][Full Text] [Related]
18. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
Broccatelli F; Carosati E; Neri A; Frosini M; Goracci L; Oprea TI; Cruciani G
J Med Chem; 2011 Mar; 54(6):1740-51. PubMed ID: 21341745
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and pharmacological activity of the stereoisomers of GP-88, a propafenone-type modulator of multidrug resistance.
Chiba P; Rebitzer S; Richter E; Hitzler M; Ecker G
Bioorg Med Chem Lett; 1998 Apr; 8(7):829-32. PubMed ID: 9871549
[TBL] [Abstract][Full Text] [Related]
20. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
